Medical Doctor Program year 2022 Reported 2019–2022 Source: CMS Open Payments, 2026 publication

Atalie Thompson

Glaucoma Specialist Durham, NC Medical Doctor

NPI 1366852303 CMS profile 5703450

Duke Eye Center 2351 Erwin Road, 2351 Erwin Road, Durham, NC 27710

Open in the dashboard

General payments

$2,140

4 records reported · program years 2019–2022

Research payments

$0

Paid to them · None reported · program years 2019–2022

Ownership & investment interest

$0

None reported

Through program year 2022, Atalie Thompson of Durham, NC is reported in the CMS Open Payments database as having received $2,140 across 4 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 41st percentile of Glaucoma Specialist profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

2 rows
Year Kind Relative to this record's peak year Amount Records
2022 General $2,040 3
2019 General $100 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Atalie Thompson
  • Glaucoma Specialist median
  • Middle half of Glaucoma Specialist
  • National median

In program year 2025, general payments to Atalie Thompson were reported at $0. Among 370 Glaucoma Specialist profiles paid that year, the median was $597 and the middle half received between $244 and $1,607.

Show as a table
Year Atalie Thompson Glaucoma Specialist median Middle half National median
2019 $100 $433 $150–$1,170 $163
2020 $0 $242 $74–$693 $114
2021 $0 $324 $122–$936 $132
2022 $2,040 $399 $121–$1,081 $149
2023 $0 $458 $190–$1,208 $160
2024 $0 $558 $215–$1,359 $164
2025 $0 $597 $244–$1,607 $169

Breakdown

Who paid General payments · program years 2019–2022
  1. Topcon Medical Systems, Inc. $2,021 2 payments
  2. Aerie Pharmaceuticals, Inc. $100 1 payment
  3. Glaukos Corporation $19 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2022
  1. Consulting Fee $2,000 1 payment
  2. Food and Beverage $119 2 payments
  3. Travel and Lodging $21 1 payment
Products named General payments · program years 2019–2022
  1. IMOVIFA $2,000 1 payment
  2. Rhopressa $100 1 payment
  3. Rocklatan $100 1 payment
  4. iStent inject W $19 1 payment
  5. ISTENT $19 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 14 drugs

Part D claims

1,324

Median for Ophthalmology: 891

Drug cost

$52,240

Median for Ophthalmology: $68,233

Branded share of claims

30.3%

Median for Ophthalmology: 29.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Rhopressa Netarsudil Mesylate Brand 30 $13,902
Lumigan Bimatoprost Brand 30 $8,113
Brimonidine Tartrate Generic 183 $6,546
Latanoprost Generic 470 $4,870
Alphagan P Brimonidine Tartrate Brand 11 $4,551
Dorzolamide-Timolol Dorzolamide Hcl/Timolol Maleat Brand 319 $4,427
Combigan Brimonidine Tartrate/Timolol Brand 11 $2,212
Brinzolamide Generic 13 $1,658
Prednisolone Acetate Generic 50 $1,639
Dorzolamide Hcl Generic 70 $1,563

The 10 drugs with the highest cost, of 14 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,260 Part D prescribers listed as Ophthalmology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 25 billing codes

Paid by Medicare

$24,127

Medicare's payments for the services billed

Medicare patients

88

Average age 75

Services billed

348

56 women, 32 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 74%
Arthritis 41%
Chronic kidney disease 30%
Diabetes 28%
Depression 25%
Osteoporosis 24%
Ischemic heart disease 19%
COPD 16%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

4 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Glaucoma Specialist in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2022

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record